Severe Thyroid Eye Disease Trials Show Hit-and-Miss Results
Monday, February 26, 2018 | Medical Studies
Efforts to better address the ongoing clinical challenge of treating moderate-to-severe Graves' orbitopathy show some potential benefits from the addition of mycophenolate mofetil to the standard of care, methylprednisolone, no benefit from the addition of radiotherapy to oral steroids, and inconclusive results with the addition of azathioprine to oral steroids, according to a report in Medscape.
These latest findings are from two clinical trials published online January 30 in The Lancet Diabetes & Endocrinology.
"Based on the results ... radiotherapy should not be considered as first-line treatment of moderate-to-severe Graves' orbitopathy, while the addition of widely available, low-dose mycophenolate mofetil to the standard treatment regimen of high-dose intravenous glucocorticoids could improve treatment outcome with limited side effects," Robin Peeters, MD, PhD, of the Department of Internal Medicine, Erasmus MC Academic Center for Thyroid Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands, told Medscape Medical News.
You must be logged in to leave a comment.